Knight Therapeutics Inc.
GUD.TOTSXHealthcare● Active
$8.61
+$0.15(+1.77%)
Market Cap$844078767
P/E Ratio—
52W High$8.9
52W Low$5.66
Knight Therapeutics Inc. (GUD.TO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
GUD.TO · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
$0.13
Est. $0.03 · +387.4%
Revenue
$0.15B
Est. $0.11B · +29.4%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 2-Quarter EPS Beat Streak
GUD.TO reports quarterly as a TSX-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.49B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.49B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | $0.01 | — | — | — | $0.13B | — |
| ▲ Q2 FY2026 | May 7, 2026 | $0.03 | $0.13 | +387.4% | $0.15B | $0.11B | +29.4% |
| ▲ Q1 FY2026 | Mar 19, 2026 | -$0.00 | $0.09 | +2350.0% | $0.13B | $0.12B | +12.6% |
| ▼ Q4 FY2025 | Nov 6, 2025 | $0.01 | -$0.04 | -480.4% | $0.12B | $0.12B | +2.8% |
| ▼ Q3 FY2025 | Aug 7, 2025 | $0.03 | -$0.13 | -522.3% | $0.11B | $0.11B | +0.7% |
| ▲ Q2 FY2025 | May 7, 2025 | -$0.01 | $0.02 | +300.0% | $0.09B | $0.09B | +1.1% |
| ▲ Q1 FY2025 | Mar 19, 2025 | $0.02 | $0.11 | +450.0% | $0.10B | $0.09B | +13.0% |
| — Q4 FY2024 | Nov 7, 2024 | — | $0.00 | — | $0.09B | $0.09B | +5.3% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
$0.01
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
$0.13
EPS Est.
$0.03
EPS Surpr.
+387.4%
Revenue
$0.15B
Q1 FY2026
Mar 19, 2026Beat
EPS Actual
$0.09
EPS Est.
-$0.00
EPS Surpr.
+2350.0%
Revenue
$0.13B
Q4 FY2025
Nov 6, 2025Miss
EPS Actual
-$0.04
EPS Est.
$0.01
EPS Surpr.
-480.4%
Revenue
$0.12B
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
-$0.13
EPS Est.
$0.03
EPS Surpr.
-522.3%
Revenue
$0.11B
Q2 FY2025
May 7, 2025Beat
EPS Actual
$0.02
EPS Est.
-$0.01
EPS Surpr.
+300.0%
Revenue
$0.09B
Q1 FY2025
Mar 19, 2025Beat
EPS Actual
$0.11
EPS Est.
$0.02
EPS Surpr.
+450.0%
Revenue
$0.10B
Q4 FY2024
Nov 7, 2024
EPS Actual
$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.09B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.07 | $0.07 | $0.08 | 1 |
| Q3 FY2027 | $0.07 | $0.07 | $0.08 | 1 |
| Q2 FY2027 | $0.03 | $0.03 | $0.03 | 1 |
| Q1 FY2027 | $0.04 | $0.04 | $0.04 | 1 |
| Q4 FY2026 | $0.03 | $0.03 | $0.03 | 1 |
| Q3 FY2026 | $0.01 | $0.01 | $0.01 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.1B | $0.1B | $0.1B | 3 |
| Q3 FY2027 | $0.1B | $0.1B | $0.1B | 3 |
| Q2 FY2027 | $0.1B | $0.1B | $0.1B | 3 |
| Q1 FY2027 | $0.1B | $0.1B | $0.1B | 3 |
| Q4 FY2026 | $0.1B | $0.1B | $0.1B | 5 |
| Q3 FY2026 | $0.1B | $0.1B | $0.1B | 6 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +387.4% | $7.51 | $8.35 | +11.19% |
| ▲ Q1 FY2026 | Mar 19, 2026 | +2350.0% | $6.17 | $6.30 | +2.11% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -480.4% | $5.84 | $6.07 | +3.94% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -522.3% | $6.29 | $6.40 | +1.75% |
| ▲ Q2 FY2025 | May 7, 2025 | +300.0% | $6.09 | $6.07 | -0.33% |
| ▲ Q1 FY2025 | Mar 19, 2025 | +450.0% | $6.19 | $6.25 | +0.97% |
| — Q4 FY2024 | Nov 7, 2024 | — | $5.74 | $5.15 | -10.28% |
| ▼ Q3 FY2024 | Aug 8, 2024 | -199.8% | $5.54 | $5.76 | +3.97% |
Q2 FY2026+11.19%
Report Date
May 7, 2026
EPS Beat/Miss
+387.4%
Price Before
$7.51
Price After
$8.35
Q1 FY2026+2.11%
Report Date
Mar 19, 2026
EPS Beat/Miss
+2350.0%
Price Before
$6.17
Price After
$6.30
Q4 FY2025+3.94%
Report Date
Nov 6, 2025
EPS Beat/Miss
-480.4%
Price Before
$5.84
Price After
$6.07
Q3 FY2025+1.75%
Report Date
Aug 7, 2025
EPS Beat/Miss
-522.3%
Price Before
$6.29
Price After
$6.40
Q2 FY2025-0.33%
Report Date
May 7, 2025
EPS Beat/Miss
+300.0%
Price Before
$6.09
Price After
$6.07
Q1 FY2025+0.97%
Report Date
Mar 19, 2025
EPS Beat/Miss
+450.0%
Price Before
$6.19
Price After
$6.25
Q4 FY2024-10.28%
Report Date
Nov 7, 2024
EPS Beat/Miss
—
Price Before
$5.74
Price After
$5.15
Q3 FY2024+3.97%
Report Date
Aug 8, 2024
EPS Beat/Miss
-199.8%
Price Before
$5.54
Price After
$5.76
Avg Beat Reaction+3.48%
Avg Miss Reaction+3.22%
Beat Rate4 / 8 quarters
Largest Move+11.19% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: GUD.TO ends December
Knight Therapeutics Inc. (GUD.TO) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $0.13 — beating the analyst consensus of $0.03 by +387.4%. GUD.TO has beaten EPS estimates for 2 consecutive quarters. The next GUD.TO earnings date is expected around September 1, 2026.
Each quarter, investors track GUD.TO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. GUD.TO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
GUD.TO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
GUD.TO earnings · 5 questionsKnight Therapeutics Inc.'s next earnings report is expected around September 1, 2026. GUD.TO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; GUD.TO historically reports after market close (AMC).
GUD.TO earnings datewhen is GUD.TO earningsGUD.TO next earnings datewhen does GUD.TO report earningsGUD.TO earnings calendar
▸ Source: FMP · Knight Therapeutics Inc. SEC filings · US GAAP · Knight Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026